YSPSL for Prevention of Delayed Graft Function Part B
Kidney Diseases
About this trial
This is an interventional prevention trial for Kidney Diseases focused on measuring Delayed Graft Function
Eligibility Criteria
Inclusion Criteria: Patients undergoing primary cadaver renal transplants Exclusion Criteria: Patient has a planned transplant of a donor kidney from a non-heart beating donor Patient has a planned transplant of kidneys that are implanted en bloc (dual kidney transplant) or from donors < 6 years of age Patient has a planned transplant of a kidney from a donor who has received investigational therapies designed to reduce the impact of ischemia/reperfusion (I/R) injury, DGF, or other donor-related immune events Patient is planned to receive a living donor kidney; or patient is planned to receive an ABO-incompatible donor kidney
Sites / Locations
- Dumont-UCLA Transplant Center
- California Pacific Medical Center Department of Transplantation
- University of Colorado Health Sciences Center
- Shands Hospital at University of Florida
- Lifelink Foundation
- Rush University Medical Center
- Tulane University Hospital & Clinic
- Henry Ford Hospital Transplant Institute
- Saint Barnabas Medical Center
- Westchester Medical Center, New York Medical College
- University of Cincinnati, Department of Internal Medicine
- Methodist Healthcare University Hospital
- Baylor University Medical Center Transplantation Services
- The Methodist Hospital
- University of Texas, Organ Transplantation
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
1
2
3